Open an Account
search icon
1
NOTIFICATIONS
Best Algo trading app in India
Bigul

FORTIS HEALTHCARE LTD. - 532843 - Proceedings And Voting Result Under SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 With reference to the Postal Ballot Notice dated November 15, 2021, following resolution have been approved with requisite majority through e-voting: - a) To consider entering into Memorandum of Understanding/agreement to sell/ Sale Deed/ Deed of Conveyance/ Escrow Agreement and related documents for sale of immovable property by Birdie and Birdie Realtors Private Limited, a step-down subsidiary company (Special Resolution). Please find enclosed Scrutinizer's Report along with result of postal ballot in prescribed format. This is for your information and records please.
22-12-2021
Bigul

Koo App, Fortis Healthcare launch initiative to help manage exam stress

 The three-day interactive program will be held from November 26-29.
26-11-2021
Bigul

FORTIS HEALTHCARE LTD. - 532843 - Intimation Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

 In continuation to intimation made by the Company on November 17, 2021, this is to inform you that the Company has completed dispatch of postal ballot notice to its members on November 22, 2021 for seeking approval of the members by way of Special Resolution on the proposal detailed in Company's earlier intimation. Further, copies of newspaper advertisements published on November 23, 2021 in the columns of English daily 'Financial Express', all editions and Punjabi daily 'Rozana Spokesman', Mohali edition, inter-alia, intimating completion of the electronic transmission of Postal Ballot Notice along with the Postal Ballot Form to the Members, are enclosed for kind reference. This is for your kind information and records.
23-11-2021
Bigul

Fortis Healthcare Ltd - 532843 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

 In compliance of Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (SEBI LODR), this is to inform you that the Company is in process of issuing postal ballot notice to its members for seeking their approval by way of Special Resolution on the following proposal: a) To consider entering into Memorandum of Understanding/agreement to sell/ Sale Deed/ Deed of Conveyance/ Escrow Agreement and related documents for sale of immovable property by Birdie and Birdie Realtors Private Limited, a step-down subsidiary company. A copy of the postal ballot notice along with ballot form is enclosed for kind reference. Further, the said notice will be dispatched to the shareholders in early next week. An intimation with respect to completion of dispatch and related compliance will be sent once the dispatch is complete. This is for your kind information and records.
17-11-2021
Bigul

Q2FY22 Quarterly Result Announced for Fortis Healthcare Ltd.

 Highlights: Consolidated Revenues for Q2FY22 at INR 1,463 Crs, up 47% EBITDA doubles to INR 292 Crs versus INR 146 Crs in Q2FY21 PAT at INR 131 Crs versus INR 16 Crs in Q2FY21 Q2FY22 hospital business revenues grew 47.2% YoY to INR 1,098.5 Crs versus INR 746.4 Crs in Q2 FY21. Revenues in Q1FY22 were at INR 1,006.5 Crs. Covid revenue contribution to overall hospital revenues declined to 3% versus 21% in Q2 FY21 and 27% in Q1 FY22. The hospital business EBITDA was at INR 189.1 Crs versus INR 78.2 Crs in Q2FY21. EBITDA in Q1 FY22 stood at 149.6 Crs. This was primarily as a result of higher procedure volumes witnessed across key specialties. Margins of 17.2% in Q2 FY22 versus 10.5% in Q2 FY21 and 14.9% in Q1 FY22 Q2 FY22 diagnostics business gross revenues grew 42.6% YoY to INR 402.7 Crs versus INR 282.4 Crs in Q2FY21. Revenues in Q1FY22 were at INR 441.4 Crs. Non-covid revenues grew 65% versus Q2FY21. Covid contribution to overall diagnostics revenues was at 18% versus 28% in Q2FY21 and 26% in Q1FY22. The diagnostics business EBITDA was at INR 103.3 Crs versus INR 70.5 Crs in Q2 FY21. EBITDA in Q1 FY22 stood at INR 134.9 Crs Margins at 25.7% in Q2 FY22 versus 25% in Q2 FY21 and 30.6% in Q1 FY22 Net debt to EBITDA was at 0.74x for Q2FY22 versus 1.04x for Q4FY21. This was post the acquisition of the balance 50% stake in the DDRC – SRL JV in April 2021, which was funded entirely through internal accruals. Net debt was at INR 869 Crs as on September 30, 2021 reflecting a net debt to equity of 0.13x. Net debt stood at INR 849 Crs as on March 31, 2021 Ravi Rajagopal, Chairman, Board of Directors, Fortis Healthcare stated, “The quarter gone by has seen a healthy improvement in our operations led by robust growth in the non-covid business. With operations returning to near normal, we have refocussed on our strategic priorities to further strengthen our medical programs in key facilities in Delhi- NCR and Mumbai. We continue to review our portfolio of facilities and our efforts to turnaround underperforming but high potential facilities such as Fortis Escorts (FEHI) are seeing encouraging results. Investments for brownfield expansion should augment our existing operational bed capacity of close to 3900 beds by another approx. 250-300 beds in FY22. In addition, leveraging Information Technology via mediums such as the myFortis app, upgrading ERP systems, utilizing advanced business intelligence tools and digitization of medical processes would ensure a seamless experience for all our patients. The diagnostics business performance has been aided by its network expansion strategy coupled with the successful integration of the DDRC acquisition. With a strong Balance Sheet we remain well positioned to evaluate opportunities of growth and consolidation for value enhancement of all stakeholders.” Result PDF
15-11-2021
Bigul

Fortis Healthcare Q2 revenue rises 47% to 1,463 crore

 Higher growth in non-Covid business helps company's bottomline
12-11-2021
Bigul

FORTIS HEALTHCARE LTD. - 532843 - Outcome Of The Board Meeting And Disclosure Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

 Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. November 12, 2021, inter-alia, considered and approved standalone and consolidated un-audited financial results of the Company for the period ended on September 30, 2021. Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for period ended on September 30, 2021. Further, a copy of the press release and investor presentation being issued in this regard is also enclosed.
12-11-2021
Bigul

FORTIS HEALTHCARE LTD. - 532843 - Board Meeting Outcome for Outcome Of The Board Meeting And Disclosure Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

 Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. November 12, 2021, inter-alia, considered and approved standalone and consolidated un-audited financial results of the Company for the period ended on September 30, 2021. Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for period ended on September 30, 2021. Further, a copy of the press release and investor presentation being issued in this regard is also enclosed.
12-11-2021
Bigul

Fortis Healthcare Ltd - 532843 - Board Meeting Intimation for Notice Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 FORTIS HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, notice is hereby given that a meeting of the Board of Directors of the Company will be held on Friday, November 12, 2021 to, inter-alia, consider and approve un-audited financial results for the quarter and period ended September 30, 2021. Further, in continuation to our letter ref. FHL/SEC/2021-22 dated September 29, 2021 captioned 'Closure of Trading Window', it is hereby informed that the trading window of the Company for dealing in securities of the Company will remain closed till November 14, 2021. This is for your information and record please.
05-11-2021
Bigul

Covid, a game-changer for digital health in India: Fortis Healthcare CEO

 Ashutosh Raghuvanshi, MD and CEO of Fortis Healthcare speaks on the company's capex plans, non-Covid business performance, and preparation for the likely third wave
17-10-2021
Next Page
Close

Let's Open Free Demat Account